Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.
Quevedo, C.E., Cruz-Migoni, A., Bery, N., Miller, A., Tanaka, T., Petch, D., Bataille, C.J.R., Lee, L.Y.W., Fallon, P.S., Tulmin, H., Ehebauer, M.T., Fernandez-Fuentes, N., Russell, A.J., Carr, S.B., Phillips, S.E.V., Rabbitts, T.H.(2018) Nat Commun 9: 3169-3169
- PubMed: 30093669 
- DOI: 10.1038/s41467-018-05707-2
- Primary Citation of Related Structures:  
5OCG, 5OCO, 5OCT, 6FA1, 6FA2, 6FA3, 6FA4 - PubMed Abstract: 
Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition. A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site ...